DON在马拉维成人中的安全性、耐受性与药代动力学:一项1期剂量递增临床试验
本研究在马拉维布兰太尔开展开放标签、前瞻性、剂量递增1期临床试验,评估单次静脉给予DON在健康成人及无并发症疟疾成人中的安全性与药代动力学。结果显示DON总体耐受良好,较高剂量与短暂胃肠道不良事件相关,疟疾对药代动力学影响较小,为儿童脑型疟辅助治疗给药策略提供依据。
要点
- DON在健康与无并发症疟疾成人中耐受良好,相关不良事件均快速缓解。
- 较高剂量(5.0与10 mg/kg)与更频繁的恶心呕吐相关。
- 疟疾对DON药代动力学影响较小,为儿童脑型疟辅助治疗提供剂量依据。
核心结论
- DON在健康成人及无并发症疟疾成人中耐受良好,较高剂量与短暂胃肠道不良事件相关,药代动力学受疟疾影响较小。
研究设计与样本
- 开放标签、前瞻性、剂量递增1期临床试验,在马拉维布兰太尔开展,受试者为健康成人及无并发症疟疾成人,按10人剂量队列分别接受0.1、1.0、5.0或10 mg/kg单次静脉DON。
主要发现
- 所有受试者中18%在输注后12小时出现短暂无症状肌酐升高。
- 恶心呕吐在0.1和1.0 mg/kg不常见,在5.0和10 mg/kg更频繁。
- 所有DON相关不良事件快速缓解、无后遗症,健康与无并发症疟疾受试者间无显著差异。
- 健康成人最大血浆浓度随剂量成比例增加,疟疾成人呈超剂量比例增加;终末半衰期为1.7至4.1小时。
临床怎么用
- 结果支持进一步评估DON作为儿童脑型疟辅助治疗,并为给药策略提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cerebral malaria (CM) is a common cause of febrile coma among African children. Despite treatment with highly efficacious intravenous artesunate, CM remains associated with high mortality and neurologic sequelae. In a mouse CM model, the glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON) demonstrated robust efficacy as a potential adjuvant therapy. Before testing DON in children with CM, we investigated tolerability in African adults, including individuals with malaria. METHODS: We conducted an open-label, prospective, dose-escalation, phase 1 clinical trial of single-dose intravenous DON in Blantyre, Malawi. Participants included healthy adults and adults with uncomplicated malaria, enrolled in dose-cohorts of 10 and administered DON at 0.1, 1.0, 5.0, or 10 mg/kg. We assessed adverse events (AEs) and plasma pharmacokinetics. RESULTS: Forty healthy adults and 38 adults with uncomplicated malaria received DON. Transient, asymptomatic creatinine elevation occurred 12 hours postinfusion in 18% of all participants. Nausea and vomiting were uncommon at 0.1 and 1.0 mg/kg but occurred more frequently at 5.0 and 10 mg/kg DON. All DON-related AEs resolved rapidly, without sequelae, and did not significantly differ between healthy and uncomplicated malaria participants. In healthy adults, maximum plasma concentrations increased proportional to dose, but adults with malaria had greater than dose-proportional increases. Terminal half-life ranged from 1.7 to 4.1 hours. CONCLUSIONS: DON was well tolerated in healthy adults and adults with uncomplicated malaria. Higher doses were associated with transient gastrointestinal AEs. Pharmacokinetics were minimally influenced by malaria disease. These results provide critical data to guide dosing strategies for adjunctive DON in children with CM. Clinical Trials Registration. NCT05478720.
引用
- Riggle BA, Chamzas A, Gopalakrishnan M, et al. Safety, Tolerability, and Pharmacokinetics of 6-Diazo-5-Oxo-L-Norleucine in Malawian Adults With and Without Malaria: A Phase 1 Dose-Escalation Clinical Trial. J Infect Dis. 2026. PMID: 41748157. doi:10.1093/infdis/jiag121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。